Source file signed link, expires in 15 minutes
Extracted text 17
Page 1
[Organon] Proprietary Public Expose PT Organon Pharma Indonesia, Tbk December 16 ,2024
Page 2
[Organon] Proprietary
Agenda
Business Organization Sustainability Financial
Overview Structure Strategy- ESG Performance
2
Page 3
[Organon] Proprietary
Business Overview
3
Page 4
[Organon] Proprietary
4
Page 5
[Organon] Proprietary
Business Overview – Areas of Focus
Women’s Established
Biosimilar
Health Brands
Through our pipeline and portfolio, Our approach to biosimilars is Our established brands span a
we are working to deliver medicines focused on providing more range of therapeutic areas,
and devices that advance the accessible treatment options to including cardiovascular disease,
health of women through all stages patients, providers, and healthcare respiratory conditions, dermatology,
of her life journey. We focus on systems central nervous system disorders,
conditions that are unique to bone health, immunology, non-
women, affect her opioid pain management,
disproportionately or impact her menopause, and more..
differently, including fertility and
contraception, maternal health
conditions, and vaginal health.
5
Page 6
[Organon] Proprietary
AP Cluster
Indonesia, with its growing population, is now
the 4th most populous country in the world
and the 2nd most populous in the AP Cluster
after India, which has 1.45 billion people.
As part of the Organon AP Cluster, Indonesia
holds significant potential to grow in
alignment with Organon’s vision: “to give a
better and healthier every day for every
woman.”
Indonesia also plays a pivotal role in Organon’s
manufacturing network. Notably, the Pandaan
site in Indonesia stands as the only
manufacturing facility in the AP Cluster
Population : 284 Mil with 52% Males
48% Female
Land Size 1,904,569 km2
GDP Growth Rate: 5.2% ~
GDP Per Capita : 4.94 K USD
6
Page 7
[Organon] Proprietary
Communication Strategies (CV)
1.Enhancing Dyslipidemia Management
Communication Tactics:
• Develop a targeted digital campaign (webinars, infographics) to highlight LDL-C reduction’s link to MACE
prevention.
• Partner with medical societies for symposiums or expert panel discussions on CKMS awareness.
• Leverage patient testimonials to build emotional resonance with the audience.
2. Promoting Fixed Dose Combination (FDC)
Communication Tactics:
• Publish articles in medical journals to establish thought leadership.
• Create educational materials like brochures and explainer videos for HCPs.
• Engage with influencers or key opinion leaders (KOLs) to amplify advocacy for FDC solutions
7
Page 8
[Organon] Proprietary
Communication Strategies - WH
1. Advancing Contraceptive Implant Adoption
Proposed Communication Tactics:
• Launch for HCPs, focusing on technical training and Q&A sessions about implants.
• Create a robust FAQ resource and share through medical community channels.
• Showcase success stories from both patients and healthcare providers to build trust.
2. Supporting Government Partnerships for LARCs
Key Messages:
Demonstrate Organon’s commitment to public health by emphasizing affordable access and training
support through BKKBN initiatives.
Align messaging with national health objectives to gain buy-in from policymakers.
Proposed Communication Tactics:
Develop a press release campaign celebrating Organon’s collaboration with BKKBN.
Organize government roundtables to highlight the impact of Organon One Rod Implant in achieving family
planning goals.
8
Page 9
[Organon] Proprietary
Communications Initiatives
Highlight Pandaan’s Legacy and
Commitment to Health
• Message: Position Pandaan as a cornerstone
of Organon’s global supply chain and its
contribution to public health over five
Leveraging the 50th decades
Anniversary of • Action:
Pandaan – a platform • Publish a commemorative video
to support the showcasing Pandaan’s history,
achievements, and role in manufacturing
business objectives lifesaving products like Implanon NXT.
that can help • Share success stories of how healthcare
access and outcomes have improved in
strengthen Organon’s Indonesia and beyond.
position as a trusted • Drive Awareness on Key Products and
partner in healthcare Innovations
• Engage Stakeholders Through Thought
Leadership
Policy Initiatives
• Advocate for Broader Access to LARCs
• Drive Policy Discussions on
Dyslipidemia Management
9
Page 10
[Organon] Proprietary
Organization Structure
Rapat Umum Pemegang Saham
General Meeting of Sharefolders
Dewan Komisaris Komite Audit
Board of Commissionaires Audit Committee
Presiden Komisaris Ketua Chairman :
President of Commissionaire Gideon Adi Siallagan
Andreas Daugaard Joergensen
Komisaris Komisaris Independen Anggota Members:
Commissionaire Independent Commissionaire • Sony Hutahaean
Erwin Agung Gideon Adi Siallagan • Ignatius Marthinus D
Direksi
Directors
Presiden Direktur Sekretaris Perusahaan
President Director Corporate Secretary
Daniel
Yuliana
Direktur Direktur Direktur
Director Director Director
Yuliana Andri Soelastyo Alison Yeap* *Sejak 16 Dec 2024 Since Dec 16th, 2024
10
Page 11
[Organon] Proprietary
ESG
Framework
11
Page 12
[Organon] Proprietary
Environmental Sustainability Goal
2050 ambitious environmental target
12
Page 13
[Organon] Proprietary
ENVIRONMENT Near-Term Goals and Long-Term Ambitions
GHG Emissions Water Materials
Integrate Circular Economy
Integrate Water Stewardship
Long- Term
Ambitions
principles into our business models
Net Zero Emissions principles into our business to maximize resource efficiency
models
• By 2025, we will reduce our Scope 1 and 2 • By 2025, we will reduce water usage in our • By 2025, >80% (range 80%-95%) of our
GHG emissions by >25% (range 25%- 40%) operations by >5% (range 5% -15%) from sites' operational waste will be reused,
from adjusted 2020* levels. adjusted 2020* levels. recycled or otherwise used beneficially.
• By 2023, we will characterize our Scope 3 • By 2023, we will characterize the water usage • By 2022, we will have developed Organon’s
Sustainability Packaging guidelines, which will
Near-Term Goals
emissions. of our value chain.
• By 2025, >70% (range 70% - 90%) of our • By 2025, >70% (range 70% - 90%) of our drive recycled content, recyclability, and
overall spending will be with suppliers that overall spending will be with suppliers that responsible sourcing.
have GHG emission reduction programs. have water reduction programs. • From 2023, the packaging of all new products
will be designed according to Organon’s
Sustainable Packaging guidelines.
• By 2025, 30% of Organon’s legacy packaging
will be reviewed against the Organon
Sustainable Packaging guidelines to identify
opportunities to reduce environmental impact.
*Baseline will be adjusted to normal (non-covid) circumstances
13
Page 14
[Organon] Proprietary
Page 15
[Organon] Proprietary
2024 Performance Highlight
15
Page 16
[Organon] Proprietary
2024 Financial Position (YTM Sep’24 vs 2023)
16
Page 17
Thank you
Names mentioned 1 people and organisations named in the text · linked when the evidence is strong
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
No extraction attempted yet.